Previous studies have shown that the oncogenic HPV E6 proteins form a complex with the human homologue of the Drosophila tumour suppressor protein, discs large (Dlg). This is mediated by the carboxy terminus of the E6 proteins and involves recognition of at least one PDZ domain of Dlg. This region of E6 is not conserved amongst E6 proteins from the low risk papillomavirus types and, hence, binding of HPV E6 proteins to Dlg correlates with the oncogenic potential of these viruses. We have performed studies to investigate the consequences of the interaction between E6 and Dlg. Mutational analysis of both the HPV18 E6 and Dlg proteins has further de®ned the regions of E6 and Dlg necessary for complex formation. Strikingly, co-expression of wild type HPV18 E6 with Dlg in vitro or in vivo results in a dramatic decrease in the amount of Dlg protein, whereas mutants of E6 which fail to complex with Dlg have minimal eect on Dlg protein levels. The oncogenic HPV16 E6 also decreased the Dlg levels, but this was not observed with the low risk HPV11 E6 protein. Moreover, a region within the ®rst 544 amino acids of Dlg containing the three PDZ domains confers susceptibility to E6 mediated degradation. Finally, treatment of cells with a proteasome inhibitor overrides the capacity of E6 to degrade Dlg. These results demonstrate that Dlg is targeted by high risk HPV E6 proteins for proteasome mediated degradation.
Introduction
Certain Human Papillomaviruses (HPVs), such as HPV16 and HPV18, are closely associated with the development of a number of human cancers (zur Hausen and Schneider, 1987; zur Hausen, 1991) . The major transforming activity of these viruses is encoded by the E6 and E7 genes (Vousden, 1994) . These proteins contribute to the oncogenic process by inactivating key cellular proteins involved in the control of cell proliferation. E7 was demonstrated to bind and inactivate the retinoblastoma tumour suppressor protein (pRB) MuÈ nger et al., 1989) , as well as the related p107 and p130 proteins (Davies et al., 1993) . The principal activity of the tumour-associated E6 proteins is the ability to bind to the p53 tumour suppressor protein and stimulate its rapid degradation via the ubiquitin proteolytic pathway (Schener et al., 1990) . There is however, a growing list of evidence indicating that, in addition to inactivating p53, E6 has other activities which may contribute to its oncogenic potential. It has been shown that HPV16 E6 interacts with the focal adhesion protein paxillin, resulting in a disruption of the actin cytoskeleton (Tong and Howley, 1997) . The E6 oncoproteins also bind to the calcium binding protein ERC55 (E6BP) (Chen et al., 1995) , and it has been recently reported that HPV16 E6 stimulates the ubiquitin-mediated degradation of c-myc and Bak (Gross-Mesilaty et al., 1998; Thomas and Banks, 1998) .
Sequence analysis of the E6 proteins derived from high risk mucosotropic HPVs reveals a high degree of homology in their C-terminal domains. This highly conserved region of E6 is not involved in the ability of E6 to bind and promote the degradation of p53 (Crook et al., 1991; Pim et al., 1994) , suggesting that other activities important for cell transformation may be regulated by this region. Recent studies have shown that this conserved C-terminal motif of oncogenic E6 proteins mediates an interaction with the PDZ domaincontaining protein hDlg, the human homologue of the Drosophila tumour suppressor, discs large protein (DlgA) (Woods and Bryant, 1991; Lee et al., 1997; Kiyono et al., 1997) . In fact, this E6 motif (XTXV/L) is remarkably similar to the C-terminal peptide domain XS/TXV which has been shown previously to interact with the hydrophobic groove of the PDZ sites (Doyle et al., 1996; Songyang et al., 1997) . PDZ domains (PSD-95/disc large/ZO-1) are 80 ± 90 amino acid motifs present in several proteins of distinct origin and function as speci®c protein-recognition modules (Ponting and Phillips, 1995; Saras and Heldin, 1996; Kim, 1997) . They can target cytoplasmic proteins to form complexes at the inner surface of the plasma membrane, and are important for clustering membrane proteins, as well as for linking signalling molecules in multiprotein complexes at specialized membrane sites (Kim et al., 1995; Marfatia et al., 1996; Kim, 1997) . hDlg-1 (homologous to the rat SAP97 and hereafter termed DLG) belongs to the family of proteins termed MAGUKs (membrane-associated guanylate kinase homologues) (Lue et al., 1994; Muller et al., 1995) . These proteins share amino-terminal PDZ domains, an SH3 domain and a carboxy-terminal guanylate kinase (GuK) homology domain. MAGUKs are multifunctional proteins localized at the membrane-cytoskeleton interface at cell-cell junctions, where they have structural as well as signalling roles (Anderson, 1996) . hDlg is expressed in a variety of cell types including epithelia, where it is localized at regions of cell-cell contact (Lue et al., 1994) . Interestingly, mutations in Drosophila dlg causes epithelial cells to lose polarity and undergo neoplastic proliferation (Woods et al., 1996) .
Taking into account the activity of E6 with respect to p53, we initiated a series of studies to investigate the eects of E6 upon the steady-state levels of DLG. We show both in vitro and in vivo that co-expression of HPV18 E6 with DLG results in a dramatic reduction in the levels of DLG expression. Mutational analysis of both E6 and DLG shows that this eect correlates with the ability of E6 and DLG to form a protein complex. A similar activity is exerted by HPV16 E6 but not by the low risk HPV11 E6 and, in addition, the reduction in DLG levels by E6 can be reversed by proteasome inhibition. These results demonstrate that oncogenic HPV E6 proteins target DLG for proteasome mediated degradation both in vitro and in vivo.
Results
The Thr156 residue of the HPV18 E6 protein is important for binding to DLG in vitro Recent reports have shown the binding of oncogenic E6 proteins to DLG, a PDZ domain-containing protein (Lee et al., 1997; Kiyono et al., 1997) . These studies highlighted the importance of the highly conserved C-terminus of the E6 proteins for this interaction, and the similarity of this region to previously de®ned PDZ domain-binding motifs (Doyle et al., 1996; Songyang et al., 1997) . To further analyse the E6-DLG interaction, we ®rst investigated the importance of E6 Thr156 for binding DLG, since this residue represents a potential PKA phosphorylation site and is also part of the PDZ domain-binding motif (Figure 1 ). We constructed two dierent HPV18 E6 mutants: Thr156Glu and Thr156Val and tested them for the ability to bind DLG in vitro. Wild type and mutant E6 proteins were expressed by in vitro translation and subjected to GST pulldown analyses by incubation with GST-DLG fusion protein (Lee et al., 1997) . The results shown in Figure 2 demonstrate that both mutants are greatly reduced in their ability to bind DLG compared with wild type HPV18 E6. As an additional control, another mutant, Arg153Lys, bearing a point mutation in the C-terminus of E6 upstream of the PDZ domain-binding motif, was also included. As can be seen, the Arg153Lys mutant binds DLG as eciently as the wild type protein. These results demonstrate that the Thr residue at position 156 within the consensus C terminal binding motif of E6 is necessary for interaction with DLG. This is in agreement with the crystal structure of the PSD-95 PDZ domain-peptide complex, which showed that the hydroxyl oxygen of the T/S residue in the PDZ binding motif of the peptide is directly involved in the interaction with the PDZ domain (Doyle et al., 1996) .
HPV18 E6 binds to all three PDZ domains of DLG in vitro
Previous studies have shown that HPV16 E6 binds principally to the second PDZ domain of DLG (Kiyono et al., 1997) . Since HPV18 E6 has been reported to bind DLG more strongly than HPV16 E6 (Kiyono et al., 1997 ; R Weiss and R Javier, personal observations), we were interested in identifying which DLG PDZ domains were necessary for complex formation with HPV18 E6. A series of GST-DLG deletion constructs ( Figure 3A ) (Lee et al., 1997) were used to assess HPV18 E6 binding. Similar amounts of each DLG fusion protein were immobilized on PVDF membrane and then incubated with puri®ed radiola- Figure 1 Alignment of the C-terminal ends of E6 proteins derived from HPV types associated with genital infections. HPV18, 16, 45, 31, 33 and 51 are high risk HPVs associated with cervical cancer. HPV11 is a low risk type associated with benign genital lesions. The alignment was performed relative to the last cysteine of the second zinc-®nger of the E6 sequence. The conserved PDZ consensus binding site is shown belled HPV18 E6 protein probe. The binding of the HPV18 E6 protein to the DLG fusion proteins was determined by autoradiography. The results shown in Figure 3B demonstrate that HPV18 E6 binds equally well to each of the three PDZ domains of DLG. This binding is speci®c since the HPV18 E6 probe did not react with the DLG constructs NT and SH3/GuK, which lack PDZ domains. This is in contrast to the results previously obtained with HPV16 E6 which was found to bind largely to DLG PDZ2 (Kiyono et al., 1997) . These divergent results are likely to explain the apparent stronger anity of HPV18 E6 for DLG compared with HPV16 E6.
Degradation of DLG protein by HPV18 E6 in vitro
A major activity of the tumour-associated E6 proteins is the ability to target a number of cellular proteins for ubiquitin mediated degradation (Schener et al., 1990; Gross-Mesilaty et al., 1998; Thomas and Banks, 1998; KuÈ hne and Banks, 1998) . Therefore, we were interested in determining whether HPV18 E6 had a similar activity with respect to DLG. To examine this, we ®rst performed an in vitro degradation assay. DLG and HPV18 E6 were translated in vitro with rabbit reticulocyte lysate, and subsequently, were mixed together and incubated at 308C for 60 min. The proteins were then run on SDS ± PAGE, and DLG protein was detected by autoradiography ( Figure 4A ). The results show a reduced level of DLG protein following incubation with wild type E6. In contrast, no change in the levels of DLG is seen when it was incubated either with the E6 Thr156Glu mutant, which cannot bind DLG, or with control water primed reticulocyte lysate. For comparison, the same assay was performed with p53 and, as can be seen in Figure  4B , both the wild type and the mutant Thr156Glu E6 proteins similarly reduced the level of p53. Equivalent results were also obtained when the experiment was performed by simultaneously co-translating the E6 and DLG proteins and then monitoring DLG levels by SDS ± PAGE and autoradiography ( Figure 4C ). In this experiment, DLG was also co-translated in the presence of HPV16 E7 as an additional negative control. These data demonstrate that the wild type HPV18 E6 protein speci®cally stimulates the degradation of DLG in reticulocyte lysates in vitro and that this activity is dependent on the ability of E6 to interact with DLG.
DLG is targeted by HPV18 E6 for degradation in vivo
Having shown that HPV18 E6 could induce the degradation of DLG in vitro, we were next interested in analysing whether this would take place in vivo. To test this possibility, we performed a series of in vivo degradation assays. Human 293 cells were cotransfected with in¯uenza haemaglutinin (HA) epitope-tagged DLG plus either wild type or the Thr156Glu mutant of HPV18 E6. After 24 h, the cells were harvested and the levels of DLG were ascertained by Western blot analysis using an anti-HA monoclonal antibody. The results shown in Figure 5A (upper panel) indicate that the levels of DLG were greatly reduced in the presence of wild type HPV18 E6 but were unaected in the presence of the E6 Thr156Glu mutant. Therefore, HPV18 E6 targets DLG for degradation in vivo, and this correlates with the ability of E6 to bind DLG in vitro. To investigate whether E6 proteins derived from other genital HPV types could promote the degradation of DLG, we examined the HPV16 E6 and HPV11 E6 proteins in the same assay. As can be seen in Figure 5A (upper panel), HPV16 E6 also promotes degradation of DLG, albeit to a lesser extent than HPV18 E6, whereas no reduction in the levels of DLG was observed in the presence of HPV11 E6. HPV16 E6 has previously been shown to bind DLG both in vivo and in vitro; in contrast, HPV11 E6 lacks the consensus PDZ domainbinding motif and cannot bind DLG (Lee et al., 1997; Kiyono et al., 1997) . Thus, high risk HPV E6 proteins share the ability to target DLG for degradation in vivo, but low risk E6 proteins which fail to bind DLG do not.
To exclude the possibility that the reduced levels of DLG expression obtained in vivo in the presence of E6 were due to sequestration within insoluble complexes rather than degradation, we analysed the levels of the DLG protein in the insoluble fractions of cells in both the presence and absence of HPV E6. The results obtained are shown in Figure 5A (lower panel) and demonstrate that in the insoluble fractions, the levels of DLG are reduced in the presence of HPV18 E6 and to a somewhat lesser extent with HPV16 E6. In contrast there is no decrease in the levels of DLG in the presence of either the Thr156Glu mutant or HPV11 E6. This result con®rms that E6 reduces the total In order to exclude the possibility that dierences in the ability of the E6 proteins to target DLG for degradation were due to dierences in levels of E6 expression, a parallel p53 in vivo degradation assay was also performed. Saos-2 cells were transfected with a p53 expression plasmid together with either HPV18, HPV16, HPV11 E6 or the Thr156Glu HPV18 E6 mutant. The cells were harvested after 24 h and the results obtained are shown in Figure 5B . As can be seen, both HPV18 E6 and HPV16 E6 induce complete degradation of the p53 protein. This indicates that the dierences in the ability of these two E6 proteins to degrade DLG most likely re¯ects intrinsic dierences in their respective abilities to target DLG for degradation rather than dierences in their levels of expression. Likewise the Thr156Glu mutant displays almost wild type levels of p53 degradation. This con®rms in a functional assay that this mutant E6 protein is expressed and, in addition, that this region of E6 is not involved in the p53 interaction. Finally, a weak reduction in p53 levels was obtained following transfection with HPV11 E6. This is in agreement with our previous observations (Storey et al., 1998) and also demonstrates functional expression of this protein.
To determine which regions of DLG render it susceptible to E6 mediated degradation, we performed in vivo degradation assays using two truncated derivatives of DLG: DLG-NT3PDZ (amino acids 1 ± 544) contains the N-terminus and the three PDZ domains of the protein, and DLGSH3GuK (amino acids 539-end) contains the GuK and SH3 motifs but lacks the PDZ domains. Both mutants were HA-tagged and the degradation assay was performed as described above. The results shown in Figure 6 demonstrate that the levels of the DLG-NT3PDZ were reduced by wild type E6 to a level similar to that of the full length DLG (DLG FL) protein. In contrast, the levels of the DLG-SH3GuK protein, which lacks the three PDZ domains, were completely unaected by the presence of the HPV18 E6 protein. These results demonstrate that the binding of E6 to DLG is required for the degradation of DLG in vivo and, in addition, that the sequences necessary and sucient for ecient degradation of DLG by HPV18 E6 lie within the ®rst 544 amino acid residues of the protein, encompassing the three PDZ domains.
HPV18 E6 stimulates the degradation of DLG via the proteasome pathway
To characterize the mechanism by which HPV18 E6 promotes degradation of DLG, we examined the involvement of the proteasome proteolytic pathway. An in vivo degradation assay was performed as described above, but the transfected cells were treated with the proteasome inhibitor (N-CBZ-LEU-LEU-LEU-AL) for 2 h before protein extraction. The levels of DLG were ascertained by Western blotting and the results obtained are shown in Figure 7 . The presence of HPV18 E6 again results in a dramatic decrease in the levels of the DLG protein. Interestingly, addition of . After 24 h, the proteins were extracted (soluble and insoluble fractions as indicated) and equal amounts were separated by SDS ± PAGE. The levels of DLG were ascertained by Western blot analysis with anti-HA monoclonal antibody (Boehringer-Mannheim). (B) A parallel transfection was performed in Saos-2 cells with 4 mg of p53 expression plasmid in the absence or presence of 4 mg HPV18 E6 (18), the Thr156Glu (glu) mutant, HPV16E6 (16) and HPV11 E6 (11). After 24 h, the proteins were extracted and equal amounts were separated by SDS ± PAGE. The levels of p53 were ascertained by Western blot analysis with a pool of anti-p53 monoclonal antibodies proteasome inhibitor results in a partial restoration of DLG protein levels in the presence of HPV18 E6, indicating proteasome involvement in the E6 mediated degradation of DLG. It is interesting to note that DLG levels in the absence of E6 are also increased in the presence of the proteasome inhibitor suggesting that DLG may normally be regulated via the proteasome. To investigate whether DLG protein levels are regulated by ubiquitination, we performed a series of in vivo ubiquitination assays. Cells were transfected with plasmids expressing full length DLG, and the two truncated derivatives NT3PDZ and SH3GuK. After 24 h cells were extracted under denaturing conditions and DLG proteins were detected by Western blot analysis. The results obtained are shown in Figure 8A and, as can be seen, ladders increasing as multiples of 8 kd, characteristic of ubiquitination, were detected with the full length DLG and with the NT3PDZ derivative. In contrast, the SH3GuK derivative, which was not susceptible to E6 mediated degradation did not exhibit laddering. To further con®rm these observations and to show that the full length DLG protein was indeed ubiquitinated in vivo, cells were transfected with à six Histidine' tagged DLG expression plasmid together with a plasmid expressing HA tagged ubiquitin. After 24 h cells were extracted under denaturing conditions and extracts were anity puri®ed on Ni ++ agarose columns as described previously (KuÈ hne and Banks, 1998) . Bound ubiqui- Figure 8B . As can be seen, in cells expressing either DLG alone, or in the presence of HPV18 E6, speci®c retention of high molecular weight ubiquitin ladders were obtained. These results con®rm that DLG is ubiquitinated both in the absence and presence of HPV18 E6 and demonstrates that DLG levels are regulated in the cell by ubiquitination.
Discussion
The high risk HPV E6 proteins share several stretches of homology in dierent regions of the protein that de®ne speci®c functional domains. The C-terminus is very highly conserved, and it has been shown to be involved in the binding to cellular proteins bearing PDZ domains. The conserved C-terminal motif of E6 also contains an RXXT consensus sequence for the cyclic AMP-dependent protein kinase A (PKA). We have shown that the Thr156 of HPV18 E6 is critical for the in vitro binding to DLG, with both neutral and acidic charge mutations abolishing binding. Interestingly, in the case of the binding of the K + channel protein Kir2.3 to the PDZ domain-containing protein PSD-95, it has been reported that the Ser residue at the C-terminus of Kir2.3 is vital for the interaction (Cohen et al., 1996) . Moreover, this Ser residue on Kir2.3 is also a substrate for PKA, and phosphorylation was found to negatively regulate the association with the PSD-95 protein. Taken together, these data suggest that potential PKA phosphorylation of E6 may also negatively regulate E6 binding to DLG.
HPV E6 proteins can stimulate the ubiquitinmediated degradation of a number of the cellular proteins to which they bind. A number of these cellular targets are tumour suppressors, and it has been proposed that the degradation of such cellular control proteins is responsible for the oncogenic activity of E6 (Schener et al., 1990; Gross-Mesilaty et al., 1998; Thomas and Banks, 1998; KuÈ hne and Banks, 1998) . We show, both in vitro and in vivo, that the recently reported E6 target protein, DLG, is also susceptible to enhanced degradation in the presence of HPV18 E6. The Thr156Glu E6 mutant, which fails to bind to DLG, had no eect on the stability of DLG in either assay, indicating that E6's binding to DLG is important for the stimulation of degradation.
We then extended the study to E6 proteins derived from other genital HPV types. The degradation assays showed that while HPV16 E6 could reduce DLG levels, the HPV11 E6 protein had minimal eect. The C-terminal motif of HPV16 E6, ETQL, is not identical to the consensus XTXV PDZ binding domains, although a previous report has shown that HPV16 E6 is capable of binding DLG in vitro and in vivo (Kiyono et al., 1997) . In contrast, the C-terminus of HPV11 E6 lacks any homology with the consensus PDZ binding site, and does not bind to DLG in vitro (Lee et al., 1997) . It has also been shown that a mutant of HPV16 E6 which was defective in DLG binding was also defective in rat cell transformation assays (Kiyono et al., 1997) . Taken together, these results suggest that this activity of E6 may contribute to the process of transformation and carcinogenesis mediated by the high risk HPVs.
Previous studies have shown that among the three PDZ domains of DLG, the second PDZ domain is essential for HPV16 E6 binding (Kiyono et al., 1997) . In contrast, we have shown that HPV18 E6 binds eciently to each of the three isolated PDZ domains in vitro, although the assays used are not identical and this may account for some of the dierences. However, the data suggest that the HPV16 and HPV18 E6 proteins bind DLG slightly dierently, and this may be a re¯ection of dierences in the consensus PDZ binding domains of the two proteins. The in vivo degradation assays would also tend to support this conclusion since HPV16 E6 is consistently weaker than HPV18 E6 in its ability to degrade DLG. It will now be interesting to determine whether this is re¯ected in dierences in the pathology of HPV16 and HPV18, since there are a number of reports which indicate a poorer prognosis for individuals with cervical tumours harbouring HPV18 DNA rather than HPV16 DNA (Burnett et al., 1992; Franco, 1992; Zhang et al., 1995) .
The in vivo degradation assays performed with the deletion derivatives of DLG showed that the amino terminus and the three PDZ domains are sucient for degradation by E6. In contrast, deletion of this region renders DLG resistant to E6 mediated degradation, and demonstrates that the region of DLG which confers susceptibility to E6 mediated degradation lies within the ®rst 544 residues of the protein.
We next investigated whether the reduction in DLG protein levels in the presence of E6 was proteasome mediated. The results demonstrated that the treatment of cells with a speci®c proteasome inhibitor partially stabilized DLG protein in the presence of E6. Complete protection of DLG over the time frame of the assay was never attained. Whether this is a re¯ection of a very high DLG turnover, low levels of DLG translation or a combination of the two, remains to be determined. We also noted that DLG levels increased following proteasome inhibition in the absence of E6 protein, indicating that DLG may be normally regulated via the proteasome. This was investigated further with a series of assays designed to determine whether DLG was indeed ubiquitinated. In the absence of E6, full length DLG and the NT3PDZ derivative were found to form high molecular weight complexes indicative of ubiquitinylation. Strikingly, the SH3GuK derivative of DLG which was not susceptible to E6 mediated degradation did not form these high molecular weight complexes. Using His tagged DLG with HA tagged ubiquitin (Treier et al., 1994) it was further possible to demonstrate that DLG is modi®ed by ubiquitin both in the absence and presence of HPV18 E6 protein in vivo. These results enable us to conclude that DLG is indeed normally regulated through ubiquitination which implies turnover via the proteasome.
The biological signi®cance of the degradation of DLG by E6 in natural infections can be addressed by considering the functions of DLG. DLG is expressed in epithelial cells, the natural host cells of HPV (Lue et al., 1994) . Epithelia form sheets of polarized cells, with the apical and basolateral sides separated by tight junctions (Kim, 1997) , and DLG is requried for the organization of these junctional complexes. Tight junctions form a continuous intercellular contact and their absence is associated with defective cell-cell adhesion, a loss of cell polarity and unregulated proliferation (Anderson, 1996; Woods et al., 1996) . Maintenance of cell polarity is crucial for normal dierentiation, and the localization of polarity signalling receptors to the basolateral membrane is apparently mediated by PDZ proteins (Woods and Bryant, 1993) . Reducing the levels of DLG may contribute to a disorganization of these tightly controlled signal transduction pathways. This could lead to a loss of control of cell proliferation or to an alteration in the proper pattern of keratinocyte dierentiation. Signi®cantly, the well-characterized Dlg-A of Drosophila was shown to form part of a developmental pathway essential for blocking cell proliferation, invasion and migration in a de®ned pattern. In addition, it was found that invasive cells bearing certain Dlg-A mutations resemble malignant cells in several ways, including migratory ability (Goode and Perrimon, 1997). The fact that high risk HPV E6 proteins are able to modulate DLG abundance may also contribute to the invasiveness of cancerous cells infected by these viruses.
In summary, degradation of DLG would be expected to induce alterations in DLG dependent signal transduction pathways, leading to changes in cytoskeletal organization and cellular migration. These alterations could contribute to the transformed, undierentiated phenotype of cells expressing high risk HPV E6 proteins.
Materials and methods

Plasmids
The E6, E7 and p53 proteins were cloned under the control of the CMV promoter into the pCDNA-3 expression plasmid. The E6 mutants were constructed using PCR directed mutagenesis. HA-tagged SAP97 expression plasmid was kindly provided by Kyung-Ok Cho and the His tagged derivative was obtained by subcloning SAP97 in frame into à six His' containing pCDNA-3 expression plasmid. Deleted derivatives of SAP97 were expressed from the CMV promoter in the GW1 plasmid . pGEX-2T-SAP97 was described previously (Lee et al., 1997) as was the HA-tagged ubiquitin expression plasmid (Treier et al., 1994) .
Cells and tissue culture
Human 293 and Saos-2 cells were grown in DMEM with 10% foetal calf serum. All the transient transfections were carried out using the calcium phosphate precipitation procedure as described previously (Matlashewski et al., 1987) .
GST fusion protein expression and binding assays
GST-SAP97 fusion protein puri®cation and GST pulldown assays were performed as described previously (Thomas et al., 1995) . Protein blotting assays using truncated derivatives of GST-DLG fusion proteins with radiolabelled HPV18 E6 were done as described previously (Lee et al., 1997) .
In vitro and in vivo degradation assays
The in vitro degradation assays were performed as described previously (Pim et al., 1994) . For the in vivo assays cells were harvested in extraction buer (250 mM NaCl, 0.1% NP40, 50 mM HEPES pH 7.0, 1% aprotinin) 24 h after transfection. Equal amounts of proteins were separated by SDS ± PAGE and transferred to nitrocellulose. The levels of remaining HAtagged DLG or p53 were determined by immunoblot analysis using either the anti-HA monoclonal antibody (BoehringerMannheim) or a pool of anti p53 monoclonal antibodies, pAb1801, 1802 and 1803 (Banks et al., 1986) . Blots were developed using the Amersham ECL technique according to the manufacturer's instructions. Cells were treated with the proteasome inhibitor (N-CBZ-LEU-LEU-LEU-AL, 40 mM), as indicated in the text, 2 h prior to protein extraction.
In vivo ubiquitination assays
Cells were transfected with His tagged DLG together with a plasmid expressing HA-tagged ubiquitin. After 24 h extracts were prepared as described previously (KuÈ hne and and anity puri®ed on Ni ++ agarose columns. Bound ubiquitin was detected by Western blot analysis with anti HA monoclonal antibodies.
